Media stories about AbbVie (NYSE:ABBV) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AbbVie earned a media sentiment score of 0.01 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.3603612317345 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
Shares of NYSE:ABBV traded down $0.41 during mid-day trading on Friday, reaching $92.60. 4,754,353 shares of the stock were exchanged, compared to its average volume of 7,486,538. The company has a debt-to-equity ratio of 6.07, a quick ratio of 1.18 and a current ratio of 1.28. The company has a market cap of $147,697.38, a PE ratio of 16.54, a PEG ratio of 0.89 and a beta of 1.61. AbbVie has a one year low of $63.55 and a one year high of $125.86.
AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, January 26th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.44 by $0.04. The business had revenue of $7.74 billion during the quarter, compared to the consensus estimate of $7.53 billion. AbbVie had a return on equity of 158.15% and a net margin of 18.82%. AbbVie’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period last year, the company earned $1.20 earnings per share. research analysts predict that AbbVie will post 7.55 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be issued a dividend of $0.96 per share. The ex-dividend date is Thursday, April 12th. This is an increase from AbbVie’s previous quarterly dividend of $0.71. This represents a $3.84 dividend on an annualized basis and a dividend yield of 4.15%. AbbVie’s dividend payout ratio (DPR) is presently 68.57%.
AbbVie declared that its board has initiated a share buyback program on Thursday, February 15th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board believes its shares are undervalued.
A number of equities research analysts have recently commented on ABBV shares. Credit Suisse Group set a $135.00 price target on AbbVie and gave the stock a “hold” rating in a research report on Monday, January 29th. Leerink Swann lowered AbbVie from an “outperform” rating to a “market perform” rating and set a $127.00 price target on the stock. in a research report on Monday, January 29th. Jefferies Group set a $145.00 price target on AbbVie and gave the stock a “buy” rating in a research report on Monday, February 26th. BMO Capital Markets set a $84.00 price target on AbbVie and gave the stock a “hold” rating in a research report on Thursday, January 11th. Finally, Zacks Investment Research lowered AbbVie from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $117.85.
In other AbbVie news, CFO William J. Chase sold 70,928 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $117.18, for a total value of $8,311,343.04. Following the completion of the transaction, the chief financial officer now directly owns 203,391 shares in the company, valued at $23,833,357.38. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Robert A. Michael sold 992 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $120.31, for a total value of $119,347.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 211,197 shares of company stock valued at $24,585,575. 0.07% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact AbbVie (ABBV) Stock Price” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/21/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-abbvie-abbv-stock-price.html.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.